Schonfeld Strategic Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,300	Closed	-$108K	–	2154
2023 Q2	$108K	Buy	30,300 +12,900	+74%	+$41.4K	﹤0.01%	1708
2023 Q1	$37.9K	Buy	+17,400	New	+$55.3K	﹤0.01%	1796
2022 Q4	–	Sell	-16,400	Closed	-$106K	–	2896
2022 Q3	$106K	Sell	16,400 -64,000	-80%	-$518K	﹤0.01%	2531
2022 Q2	$368K	Buy	80,400 +67,400	+518%	+$360K	﹤0.01%	1540
2022 Q1	$112K	Buy	+13,000	New	+$133K	﹤0.01%	2201

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Schonfeld Strategic Advisors's ORMP Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2023, closing a stake of 30,300 shares — an estimated $108K sold.

Schonfeld Strategic Advisors first reported a position in ORMP in Q1 2022 and held it in 5 quarters. The position peaked at $368K in Q2 2022. 56 funds tracked by Wall St. Rank hold ORMP as of Q3 2023.

Schonfeld Strategic Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 30,300 Oramed Pharmaceuticals shares in Q3 2023, an estimated $108K.
Schonfeld Strategic Advisors first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Schonfeld Strategic Advisors's Oramed Pharmaceuticals position peaked at $368K in Q2 2022.
56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.